Follow-up to HomeBiogas: How Much Real Funding Room Is Left

How Much Real Funding Room Is Left

The main article already established that HomeBiogas’s problem is not whether it can sign another memorandum. It is whether the company has enough time and money to reach the point where the carbon projects begin funding themselves. This follow-up isolates only that question: how much liquidity was truly left at the end of 2025, what part of the funding stack is actually free cash, and what already comes with an offsetting obligation.

The short answer: funding room is narrower than the cash balance alone suggests. The company ended the year with $1.862 million of cash and another $92 thousand of restricted cash. Against that, it discloses contractual financial obligations of $1.426 million due within 6 months and another $72 thousand due in 6 to 12 months. That means that even before asking what 2026 operating burn will look like, most of the year-end liquidity stack was already spoken for by near-term pressure.

That also explains why the going-concern note did not disappear even though the 2025 operating picture looked better. Operating cash flow was still negative $2.246 million, and management writes that even after preparing a 24-month budget, the group will not be able to continue in its current format and meet its obligations in the foreseeable future. So the right question is not how much financing one can imagine on paper. It is how much runway exists without double counting conditional cash, dilutive capital or money that can come back as a liability.

This chart intentionally uses an all-in cash flexibility frame, meaning how much cash is really left after near-term commitments already sitting on the company. That is the right lens here, because the current debate is not how much the business could generate in the future if every project matures. It is how much room is left before HomeBiogas needs another external source of funding. On that basis, $1.954 million of end-2025 liquidity looks less like a cushion and more like a short bridge.

Even the "investing" line looks better than it really is

There is another point that is easy to miss in a quick read of the cash-flow statement. Investing cash flow was positive $280 thousand in 2025. That does not mean the business suddenly started generating excess cash through investment activity or that a new internal funding engine opened up. That line included $146 thousand from collection of lease receivables, $123 thousand from the change in restricted cash and $20 thousand from the sale of fixed assets. In other words, part of the improvement came from releasing cash that was already tied up or from small disposals, not from the business moving to self-funding status.

That distinction matters, because once the cash flow, the going-concern note and the maturity schedule are read together, the picture becomes simpler: 2025 improved the direction of burn, but it still did not create an internal funding layer capable of carrying a regulatory project rollout.

2025 Bought Time Through Equity, Not Through Operations

Once the 2025 financing layer is unpacked, it becomes clear that the main bridge came from equity. Total financing cash flow was positive $943 thousand, but that figure included $1.263 million of net proceeds from private placements, which were partly consumed again by $81 thousand of lease interest, $79 thousand of lease principal and $160 thousand of Innovation Authority grant repayment.

In other words, the 2025 raises were not an extra reserve on top of the business. They were the reason the financing line stayed positive at all. Without that $1.263 million, the financing section itself would have turned negative, and year-end cash would have looked very different.

Two placements, limited proceeds, and no illusion of closure

In June 2025 the company raised NIS 1.5 million in a private placement to Yossi Dahan 2019 Ltd. at NIS 1 per share. In July 2025 it raised another roughly NIS 3 million in a private placement to five investors at NIS 1.1 per share. Together, those two placements created 4.210 million new shares in 2025 and produced net proceeds of $1.263 million.

The analytical meaning is not just that the company managed to bring in capital. The more important point is that even after two private placements in the same year, HomeBiogas still ended 2025 with a going-concern note and with liquidity that barely covers the near-term maturity wall. This is no longer a story of one more small raise and the problem is solved. It is a sign that every round buys time, but still does not create a real gap between the company and the next round.

Internal Support Existed, but It Is Not a Cushion You Can Underwrite

At year-end 2025 the company carried $85 thousand of payables to controlling parties. The note states explicitly that this balance reflects management-fee debt, that the maturity of those amounts was deferred in order to improve the company’s cash position, that the debt bears no stated interest, and that there is no formal commitment regarding when those amounts may be withdrawn. That is real support, but it needs to be read correctly: it is not equity, not a permanent waiver, and not new money. It is delayed cash outflow that may still leave the company later.

The related-party note sharpens the point further. As of December 31, 2025 the company had an accrued liability of NIS 118 thousand to Oshik Efrati for unpaid management fees as CEO and NIS 95 thousand to Erez Lentzer for unpaid management fees as deputy CEO, COO and CFO, both starting from November 2025. So even within late 2025 itself, part of management cash compensation had already been pushed forward.

But the more important point comes next. In August 2025, in connection with the review of the company’s June 30, 2025 financial position, two former joint controlling shareholders who still serve as officers undertook not to withdraw management fees if the 12-month budget would not support ongoing operations. On March 9, 2026, the same day the accounts were approved, the board received notice that this undertaking had been canceled.

That is a key point. At the thesis level, the company entered year-end 2025 with soft internal cash support, but it left the reporting date without the ability to assume that this support would remain open. So any generous runway read that assumes insiders will simply continue leaving cash inside the business is no longer supported in the same way after March 9, 2026.

The Klik Prepayment and the Draft Convertible Bond Add Funding, but Not of the Same Quality

The February 2026 Klik amendment looks, at first glance, like good funding news. Up to $770 thousand of advance payment, with no discount, against the Ghana project is clearly better than a plain dilutive equity infusion. But the structure of the arrangement says something important: this is not money that comes in and stays fully free in the cash balance.

First, the amount is to be paid in two installments and only subject to milestones related to system installations and additional system orders. Second, the prepayment is recorded as a liability to Klik and offset against future invoices. Third, if by September 30, 2028 the company has not supplied carbon rights in an aggregate amount equal to the prepayment, the remaining balance must be returned to Klik within 30 days, without interest. Fourth, from the second quarter of 2027 onward, Klik is entitled to adjust its purchase commitment downward in line with project progress.

From a cash perspective, that means the prepayment can be very helpful in getting the execution phase moving. It is also a serious signal from the buyer. But it does not turn the company’s funding problem into a solved one. It is bridge financing tied to performance, and it depends on HomeBiogas delivering installation pace, approvals and carbon-credit generation.

And what does the bond draft say about the cost of debt?

The December 2025 draft convertible bond documents also deserve attention precisely because they reveal the kind of financing structure the market may demand if the company chooses the debt route. First, this is only an examination of a possible issuance. The company states explicitly that there is no certainty regarding the issuance itself, its timing, its size or its terms. But even as a draft, the document says a lot.

The first clause that matters is the debt-service reserve. The company undertakes to place, out of issuance proceeds, a dedicated cash cushion equal to one full annual interest payment for the bond series, in a trust account pledged first-ranking to the trustee. That matters not because the exact coupon has not yet been set, but because the economic meaning is already clear: not every gross shekel raised would remain available for operations. Part of the proceeds would be trapped up front for creditors.

The second clause is an absolute distribution ban. Until the debt is repaid in full, finally and precisely, the company would not be allowed to make any distribution, including dividends. In a company like HomeBiogas this does not change immediate cash behavior because there is no realistic near-term dividend case anyway. But it does show how debt, if it comes, would be priced: as survival and execution funding, not as relaxed growth capital.

The third clause is a negative pledge. The company would not be allowed to create a floating charge over all of its direct assets unless bondholders approve it in advance or receive an equivalent pari passu charge. At the same time, the draft makes clear that the restriction does not apply to specific-asset security and does not apply to subsidiaries. That is an important nuance: the document protects bondholders against a broad competing lien at the parent level, but still leaves the company room to build financing at the asset or subsidiary level.

In addition, the draft offers a simple but not forgiving debt profile: principal in a single payment on December 31, 2030, with fixed annual interest payments every December 31 starting in 2026. So even before final issuance size is known, the signal is already visible. If the company goes to debt markets, those markets are likely to demand a dedicated cash reserve, structural restrictions and protection against competing group-level claims.

So How Much Runway Is Really Left?

If the funding layers are ranked by quality, the picture becomes fairly sharp:

The cash that was already in the company at the end of 2025 is not large enough to create comfort. Once it is set against the financial obligations due within 12 months, only a narrow residual remains even before 2026 operating burn enters the picture.

The equity raised in 2025 bought time, but it did not buy closure. Two private placements in the same year improved the position, yet the report was still signed with a going-concern note.

The support from inside the company is too soft to build a thesis on. Deferred management-fee cash outflow and accumulated payables to controlling parties help at the margin, but they are small relative to the funding need and became less reliable exactly at the reporting date.

Klik can be a good bridge, but it is a conditional bridge. If the project progresses, it is helpful cash. If not, it is a liability that can come back.

Even debt, if it comes, will not look like simple money. The draft bond terms already show that some proceeds may be trapped in a debt-service cushion and that the funding market will ask for protections before extending more runway.

That is why the broader conclusion from the main article actually becomes stronger in this follow-up. HomeBiogas’s 2026 bottleneck is not demand, and not even just approvals. It is funding quality. The company has already shown that it can build a commercial story that attracts carbon buyers and investors. It still has not shown that it has an equity or debt layer strong enough to carry the execution phase without very quickly turning into another liquidity test.